Sage Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2013 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Sage Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2013 to Q4 2023.
  • Sage Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $735M, a 23.9% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $735M +$142M +23.9% Dec 31, 2023 10-K 2024-02-14
Q4 2022 $593M +$123M +26.1% Dec 31, 2022 10-K 2024-02-14
Q4 2021 $471M +$94.5M +25.1% Dec 31, 2021 10-K 2023-02-16
Q4 2020 $376M -$107M -22.2% Dec 31, 2020 10-K 2022-02-24
Q4 2019 $483M +$175M +56.7% Dec 31, 2019 10-K 2021-02-24
Q4 2018 $308M +$103M +50.1% Dec 31, 2018 10-K 2020-02-27
Q4 2017 $205M +$70.4M +52.1% Dec 31, 2017 10-K 2019-02-19
Q4 2016 $135M +$66M +95.6% Dec 31, 2016 10-K 2018-02-22
Q4 2015 $69.1M +$40.8M +144% Dec 31, 2015 10-K 2017-02-24
Q4 2014 $28.3M +$15.6M +122% Dec 31, 2014 10-K 2016-02-29
Q4 2013 $12.7M Dec 31, 2013 10-K 2015-03-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.